Study variable | Number of studies | Number of subjects |
---|---|---|
Studies included | 26 | 844 |
Country | ||
 United States | 5 | 45 |
 United Kingdom | 2 | 16 |
 Brazil | 3 | 43 |
 China | 4 | 366 |
 India | 4 | 195 |
 South Korea | 2 | 82 |
 Japan | 2 | 24 |
 Spain | 1 | 10 |
 Taiwan | 1 | 30 |
 Cuba | 1 | 5 |
 Russia | 1 | 10 |
Stroke phase | ||
 Hyper-acute/acute/sub-acute | 15 | 597 |
 Chronic | 12 | 247 |
 Stroke type | ||
 Ischaemic | 20 | 421 |
 Ischaemic + haemorrhagic | 5 | 77 |
 Haemorrhagic | 2 | 346 |
Stem cell characteristics | ||
 Cell type | ||
  Human bone marrow-derived MSC/MNC | 18 | 698 |
  Human fetal neural stem/progenitor cells | 3a | 67 |
  Umbilical mesenchymal stem cells | 1 | 14 |
  Porcine fetal cells | 1 | 5 |
  Human embryonic neuronal cells | 2 | 19 |
  Peripheral blood haematopoietic stem cells | 1 | 30 |
 Cell source | ||
  Allogeneic | 8 | 134 |
  Autologous | 18 | 710 |
 Route of administration | ||
  Intra-arterial | 6b | 57 |
  Intracerebral | 9c | 405 |
  Intravenous | 11b | 332 |
  Intrathecal | 2c | 256 |
 Time between stroke onset and stem cell transplantation | ||
  < 3 months | 13d | 567 |
  > 3 months | 14d | 283 |
Study design | ||
 RCT | 6 | 390 |
 Non-RCT (case–control design) | 4 | 280 |
 Non-RCT (historic control) | 1 | 10 |
 Single-arm open-label design | 15 | 97 |
Provision of rehabilitation | ||
 RCT | ||
  Yes | 4 |  |
  No | 1 |  |
  Not reported | 1 |  |
 Non-RCT | ||
  Yes | 1 |  |
  No | 4 |  |
  Not reported | 14 |  |